ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

1:00PM-2:30PM: Abstract Number: 2533

Genome-wide Association of Rheumatoid Arthritis in the African Ancestry Identifies HLA Amino Acid Polymorphisms of Risk

Abstracts: Genetics, Genomics & Proteomics

1:00PM-2:30PM: Abstract Number: 2576

Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics

1:00PM-2:30PM: Abstract Number: 2542

Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis

Abstracts: RA – Animal Models

1:00PM-2:30PM: Abstract Number: 2585

Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study

Abstracts: SpA Including PsA – Treatment II

1:00PM-2:30PM: Abstract Number: 2538

HLA-DRB1 Rheumatoid Arthritis (RA) Risk Alleles Preferentially Select TRBJ2-3-containing CD4 T Cells in RA Patients

Abstracts: Genetics, Genomics & Proteomics

1:00PM-2:30PM: Abstract Number: 2568

Incidence of First Fracture in RA Is Increasing Faster Than the General Population

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

1:00PM-2:30PM: Abstract Number: 2550

Infiltrating and Resident Macrophages in Lupus Nephritis: Scar Associated Macrophage Phagocytic Dysfunction and Fibroblast Activation

Abstracts: SLE – Animal Models

1:00PM-2:30PM: Abstract Number: 2546

Lipocalin-2 Drives Neuropsychiatric and Cutaneous SLE Through Regulation of Immune Cell Recruitment in Target Organs

Abstracts: SLE – Animal Models

1:00PM-2:30PM: Abstract Number: 2591

Lupus-Related Reproductive Health Experiences and Needs of Women of Childbearing Age: A Qualitative Study

Abstracts: ARP Interprofessional I: Epidemiology & Methods

1:00PM-2:30PM: Abstract Number: 2551

Modified Delphi Process to Propose an Equity Measurement Roadmap in Rheumatology

Abstracts: Healthcare Disparities in Rheumatology

1:00PM-2:30PM: Abstract Number: 2548

NADPH Oxidase in B Cells and Macrophages Protects Against Murine Lupus by Regulation of TLR7

Abstracts: SLE – Animal Models

1:00PM-2:30PM: Abstract Number: 2547

Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

Abstracts: SLE – Animal Models

1:00PM-2:30PM: Abstract Number: 2543

Novel IgG Degrader BHV-1300 Demonstrates the Ability to Remove Anti-bDMARD ADA and Allows for Co-administration with Fc-containing Biologics

Abstracts: RA – Animal Models

1:00PM-2:30PM: Abstract Number: 2590

Pesticide Use and Incident Rheumatoid Arthritis Among Spouses in the Agricultural Health Study: An Updated Analysis

Abstracts: ARP Interprofessional I: Epidemiology & Methods

1:00PM-2:30PM: Abstract Number: 2545

Phosphodiesterase 1B Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation

Abstracts: SLE – Animal Models

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].